News - FLT1 mutation - LARVOL VERI

over1year

The Driverless Triple-Wild-Type (BRAF, RAS, KIT) Cutaneous Melanoma: Whole Genome Sequencing Discoveries. (PubMed, Cancers (Basel))

The two regressed melanomas of this cohort shared a 17-gene mutation signature, containing genes involved in antitumor immunity and several cell surface receptors. Even with this comprehensive genomic approach, a few cases remained driverless, suggesting that unrecognized drivers are hiding among passenger mutations.

over 1 year ago

Journal • Tumor mutational burden • IO biomarker

BRAF (B-raf proto-oncogene) • TMB (Tumor Mutational Burden) • NRAS (Neuroblastoma RAS viral oncogene homolog) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NF1 (Neurofibromin 1) • RAS (Rat Sarcoma Virus) • FLT1 (Fms-related tyrosine kinase 1)

EGFR mutation • BRAF wild-type • NF1 mutation • RET mutation • NRAS wild-type • KIT wild-type • NTRK1 mutation • FLT1 mutation

almost2years

Familial uterine leiomyoma-associated germline oncogenic mutant VEGFR1 is sensitive to mTOR inhibitor. (PubMed, Sci Bull (Beijing))

No abstract available

almost 2 years ago

Journal

FLT1 (Fms-related tyrosine kinase 1)

EGFR mutation • FLT1 mutation

almost3years

Whole Exome Sequencing Identifies Somatic Variants in an Oral Composite Hemangioendothelioma Characterized by YAP1-MAML2 Fusion. (PubMed, Head Neck Pathol)

Whole exome sequencing (WES) identified three missense mutations FLT1 [p.R1016G], PIK3CA [p.H1047L], and C11orf42 [p.A304P] and a mitochondrial frameshift insertion MT-ND4 [c.1107_1108insC; p.P370fs]. These WES results suggest that FLT1 and/or PIK3CA variants may contribute to tumor growth/transformation while the MT-ND4 variant may relate to proliferation, angiogenesis and/or inhibition of apoptosis.

almost 3 years ago

Journal

PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FLT1 (Fms-related tyrosine kinase 1) • YAP1 (Yes associated protein 1) • CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • SYP (Synaptophysin) • MAML2 (Mastermind Like Transcriptional Coactivator 2)

PIK3CA mutation • PIK3CA H1047L • FLT1 mutation

3years

Soft tissue perineurioma involving the kidney: a report of two cases with an emphasis on differential diagnosis. (PubMed, Diagn Pathol)

In conclusion, renal perineurioma is rare, usually arises in the capsular areas, and is cured by resection. Low-grade dedifferentiated liposarcoma and low-grade fibromyxoid sarcoma as well as other spindle cell lesions should be considered in the differential diagnosis.

3 years ago

Clinical • Journal • Tumor Mutational Burden

TMB (Tumor Mutational Burden) • MDM2 (E3 ubiquitin protein ligase) • KMT2A (Lysine Methyltransferase 2A) • FLT1 (Fms-related tyrosine kinase 1) • FUS (FUS RNA Binding Protein)

TMB-L • FLT1 mutation

over3years

[VIRTUAL] CCR5/CCL5 gene expression in colorectal cancer (CRC): Comprehensive profiling and clinical value (ESMO 2021)

Our data show a strong association between CCR5/CCL5 gene expression and distinct molecular features (including CMS), TME cell infiltration, pt outcome, and treatment benefit in CRC. These findings suggest that targeting the CCR5/CCL5 axis may have relevant clinical applications in selected CRC subgroups and chemokines CCL5 & CCL2 may be important targets in TME.

over 3 years ago

Clinical • Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker

PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • FLT3 (Fms-related tyrosine kinase 3) • APC (APC Regulator Of WNT Signaling Pathway) • FLT1 (Fms-related tyrosine kinase 1) • CCL5 (Chemokine (C-C motif) ligand 5) • CCR5 (C-C Motif Chemokine Receptor 5) • CCL2 (Chemokine (C-C motif) ligand 2)

APC mutation • CCR5 expression • FLT1 mutation

Avastin (bevacizumab)